GPB Scientific Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • GPB Scientific's estimated annual revenue is currently $4.5M per year.(i)
  • GPB Scientific's estimated revenue per employee is $155,000

Employee Data

  • GPB Scientific has 29 Employees.(i)
  • GPB Scientific grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.7M3546%N/AN/A
#2
$1.4M9-10%N/AN/A
#3
$4.3M284%N/AN/A
#4
$29.3M1896%N/AN/A
#5
$1.1M70%N/AN/A
#6
$3.5M45-52%$56.5MN/A
#7
$0.3M20%N/AN/A
#8
$4.5M2921%N/AN/A
#9
$1.9M129%N/AN/A
#10
$2.9M3719%N/AN/A
Add Company

GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for chimeric antigen receptor T cell (CAR-T) therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.

keywords:N/A

N/A

Total Funding

29

Number of Employees

$4.5M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

GPB Scientific's People

NameTitleEmail/Phone
1
Chief Technology OfficerReveal Email/Phone
2
VP Product Development and ManufacturingReveal Email/Phone

GPB Scientific News

2022-04-19 - The R&D Dept.: Local patent roundup for 4.20.22

Assignee: GPB Scientific, Inc. (Richmond) & University of Maryland, Baltimore Baltimore, Maryland) & The Trustees of Princeton University...

2022-04-17 - Delta updates its statement calling COVID a 'seasonal virus ...

Passengers, medical experts and public health leaders promptly turned to social media to dispute the claim and call out the lack of scientific...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M290%N/A
#2
N/A297%N/A
#3
$6.7M297%N/A
#4
N/A2961%N/A
#5
$6.7M29-6%N/A